The changing legal landscape of French medtech reimbursement
This article was originally published in Clinica
Executive Summary
The final shape of France's future reimbursement system is currently being hammered out. Jacques Biot, president and CEO of the consultancy JNB-Developpement, told Amanda Maxwell how manufacturers can prepare for the changes ahead and why medical devices cannot be viewed in isolation to pharmaceuticals.